Research Focus

Anthracyclines such as doxorubicin and daunorubicin are among the most potent antitumor drugs available and are used to treat a variety of adult as well as childhood cancers. However, these drugs cause significant cardiovascular toxicity, including acute arrhythmias and chronic cardiomyopathy in up to 16% of patients This is a devastating and largely irreversible complication and can lead to congestive heart failure and death, occurring years or even decades after a patient was exposed to the drug.

We will conduct prospective observational studies in up to 120 patients and retrospective analyses to identify and characterize patients who have experienced anthracycline-induced cardiotoxicity and drug matched controls. In parallel with GWAS examination, whole exome sequencing will be performed to identify coding mutations.

Principal Investigator

Co-PI: Mark Richards (CVRI)

Co-Investigators: Ling Lieng Has (CVRI), Lee Soo Chin (NUHS), Goh Boon Cher (NUHS), Liam Brunham (TLGM), Yap Yoon Sim (NCC), Vivianne Shih Lee Chuen (NCC), Alexandre Chan (NCC)

Principal Investigator

Co-PI: Mark Richards (CVRI)

Co-Investigators: Ling Lieng Has (CVRI), Lee Soo Chin (NUHS), Goh Boon

Cher (NUHS), Liam Brunham (TLGM), Yap Yoon Sim (NCC), Vivianne Shih

Lee Chuen (NCC), Alexandre Chan (NCC)